Respiratory syncytial virus (RSV) is the main causative factor of severe respiratory disease in immunodeficient populations, infants and children, with high incidence and mortality worldwide. Early and accurate diagnosis of RSV is essential for appropriate treatment.

Respiratory syncytial Virus (RSV)

CAS No.	Product Name	Inquiry
162401-32-3	Roflumilast Roflumilast has anti-inflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such as asthma, and chronic obstructive pulmonary disease (COPD). While Roflumilast was found to be effective in clinical trials, it produced several dose-limiting side effects including nausea, diarrhoea and headache, and development is continuing in an attempt to minimise the incidence of side effects while retaining clinical efficacy.

First
«
1
2
3
»
Last

※ Please kindly note that our services are for research use only.

Tel:
Email:

Respiratory syncytial Virus (RSV)

Roflumilast